首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

2107849

糖基化胜肽市場：按產品、分銷管道和地區分類

Glycosylated Peptide Market, By Product, By Distribution Channel, By Geography

出版日期: 2026年07月20日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

糖基化胜肽市場預計到 2026 年將達到 116.7531 億美元，預計到 2033 年將達到 208.092 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 8.6%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	116.7531億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	8.60%	2033年市場規模預測：	208.92億美元

預計在以下因素的推動下，市場將經歷強勁成長：對肽類療法的需求不斷成長、慢性病患病率上升、糖基化肽在藥物發現和疫苗開發中的應用日益廣泛，以及糖蛋白體學和肽合成技術的進步。

糖基化胜肽是指透過連接糖分子修飾的胜肽，這種修飾可以提高其穩定性、生物利用度、藥物動力學特性和治療效果。由於這些分子能夠增強藥物性能和標靶特異性，因此它們擴大被用於生技藥品、單株抗體、重組蛋白和疫苗的研發。質譜和糖蛋白體學等分析技術的進步提高了糖基化胜肽的表徵能力，從而推動了製藥和生物技術行業的研發和商業化。

市場成長也受到生物製藥研發投入增加、精準醫療日益受到重視以及糖基化胜肽在癌症免疫療法、生物標記發現、自體免疫疾病治療和感染疾病管理等領域應用不斷拓展的推動。重組DNA技術、酶促糖基化和胜肽合成技術的持續創新正在提高生產效率和產品品質。此外，策略合作的增加、產品核可以及研發經費的投入預計將在預測期內加速糖基化胜肽療法的開發和商業化進程。

市場動態

糖基化胜肽市場的發展受到技術進步、疾病負擔加重以及在生物製藥研究和治療領域應用不斷擴大等因素的共同推動。

生物製藥和標靶治療需求的不斷成長是關鍵成長要素之一。糖基化生物製藥，包括單株抗體和重組蛋白，因其穩定性提高、治療效果增強、半衰期延長和靶向特異性增強等優點而廣泛應用。生物製藥獲批數量的增加以及對胜肽類療法投資的擴大預計將顯著提升全球對糖基化胜肽的需求。

另一個主要的成長要素是癌症、糖尿病、自體免疫疾病和感染疾病等慢性疾病的日益普遍。這些疾病負擔的加重，促使人們對具有增強藥理特性的先進胜肽類療法的需求不斷成長。同時，精準醫療和基於生物標記的診斷技術的日益普及，也拓展了糖基化胜肽在個人化醫療和疾病特異性藥物研發中的應用。

重組DNA技術、酵素糖基化、先進胜肽合成、Glico和質譜分析等技術創新正在進一步改善糖基化胜肽的生產、表徵和品管。這些進步有助於提高生產效率，增強治療效果，並加速製藥和生技產業的研發進程。

然而，該市場面臨許多挑戰，例如生產流程複雜、高成本以及大規模生產中控制聚醣模式的技術難題。儘管存在這些限制因素，但預計在預測期內，對糖蛋白體學研究投入的不斷增加、生物製藥生產能力的不斷提升以及下一代胜肽療法的持續創新將創造顯著的成長機會。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、阻礙因素、機會、新產品發布、市場趨勢、區域展望以及領先企業採取的競爭策略。
本研究根據以下參數介紹了糖基化胜肽市場主要參與者的概況：公司概況、產品系列、主要發展、財務績效和策略。
透過利用本報告中提出的見解，行銷負責人和經營團隊可以就未來的產品創新、市場擴張和策略聯盟做出明智的決策。
《糖基化胜肽市場》報告的目標受群眾外包括投資者、製藥公司、生技公司、研究機構、監管機構和金融分析師等各類相關人員。
相關人員可以利用用於評估糖基化胜肽市場的系統分析框架和策略矩陣來獲得極大的益處。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第7章競爭情勢

公司簡介
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Bachem Holding AG
- GlyTech, Inc.
- Sussex Research Laboratories Inc.
- Samsung Bioepis
- Celltrion Inc.

第8章

參考
調查方法

簡介目錄

Product Code: CMI1576

Glycosylated Peptide Market is estimated to be valued at USD 11,675.31 Mn in 2026 and is expected to reach USD 20,800.92 Mn by 2033, growing at a compound annual growth rate (CAGR) of 8.6% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 11,675.31 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	8.60%	2033 Value Projection:	USD 20,800.92 Mn

The market is projected to witness strong growth owing to increasing demand for peptide-based therapeutics, rising prevalence of chronic diseases, growing adoption of glycosylated peptides in drug discovery and vaccine development, as well as advancements in glycoproteomics and peptide synthesis technologies.

Glycosylated peptides are peptides modified through the attachment of carbohydrate molecules, which improve their stability, bioavailability, pharmacokinetic profile, and therapeutic efficacy. These molecules are increasingly being used in biologics, monoclonal antibodies, recombinant proteins, and vaccine development due to their ability to enhance drug performance and target specificity. Advancements in analytical technologies such as mass spectrometry and glycoproteomics are improving the characterization of glycosylated peptides, thereby supporting research and commercialization across pharmaceutical and biotechnology industries.

The market growth is further supported by increasing investments in biopharmaceutical research, growing emphasis on precision medicine, and expanding applications of glycosylated peptides in cancer immunotherapy, biomarker discovery, autoimmune disease treatment, and infectious disease management. Continuous innovations in recombinant DNA technology, enzymatic glycosylation, and peptide synthesis techniques are improving manufacturing efficiency and product quality. In addition, increasing strategic collaborations, product approvals, and research funding are expected to accelerate the development and commercialization of glycosylated peptide therapeutics during the forecast period.

Market Dynamics

The Glycosylated Peptide Market is driven by a combination of technological advancements, increasing disease burden, and expanding applications in biopharmaceutical research and therapeutics.

One of the primary growth drivers is the increasing demand for biologics and targeted therapies. Glycosylated biologics, including monoclonal antibodies and recombinant proteins, are gaining widespread adoption due to their improved stability, enhanced therapeutic efficacy, prolonged half-life, and greater target specificity. Growing approvals of biologic drugs and increasing investments in peptide therapeutics are expected to significantly boost demand for glycosylated peptides worldwide.

Another major growth factor is the rising prevalence of chronic diseases such as cancer, diabetes, autoimmune disorders, and infectious diseases. The growing burden of these conditions is increasing the need for advanced peptide-based therapeutics with improved pharmacological properties. At the same time, growing adoption of precision medicine and biomarker-based diagnostics is expanding the application of glycosylated peptides in personalized treatment approaches and disease-specific drug development.

Technological innovations including recombinant DNA technology, enzymatic glycosylation, advanced peptide synthesis, glycoproteomics, and mass spectrometry are further improving glycosylated peptide production, characterization, and quality control. These advancements are supporting efficient manufacturing, enhancing therapeutic performance, and accelerating research across pharmaceutical and biotechnology industries.

However, the market faces challenges including high manufacturing complexity, expensive production processes, and technical difficulties associated with controlling glycosylation patterns during large-scale manufacturing. Despite these restraints, increasing investments in glycoproteomics research, expanding biologics manufacturing capacity, and continuous innovation in next-generation peptide therapeutics are expected to create significant growth opportunities throughout the forecast period.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the Glycosylated Peptide Market based on the following parameters - company highlights, product portfolio, key developments, financial performance, and strategies.
Key companies covered as a part of this study include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bachem Holding AG, GlyTech, Inc., Sussex Research Laboratories Inc., Samsung Bioepis, and Celltrion Inc.
Insights from this report would allow marketers and management authorities to make informed decisions regarding future product innovations, market expansion, and strategic partnerships.
The Glycosylated Peptide Market report caters to various stakeholders including investors, pharmaceutical companies, biotechnology companies, research organizations, regulatory authorities, and financial analysts.
Stakeholders would benefit from structured analytical frameworks and strategy matrices used in evaluating the Glycosylated Peptide Market.

Market Segmentation

By Product Insights (Revenue, USD Mn, 2021 - 2033)
Monoclonal Antibodies (mAbs)
Erythropoietin (EPO)
Other Products
By Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region Insights (Revenue, USD Mn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Key Players
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Bachem Holding AG
GlyTech, Inc.
Sussex Research Laboratories Inc.
Samsung Bioepis
Celltrion Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Product
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Market Opportunities
Impact Analysis
Market Trends
Recent Product Launches/Approvals
Regulatory Scenario
Epidemiology
PEST Analysis
Acquisition and Collaboration Scenario

4. Global Glycosylated Peptide Market, By Product, 2021 - 2033 (USD Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Monoclonal Antibodies (mAbs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
Erythropoietin (EPO)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
Other Products
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)

5. Global Glycosylated Peptide Market, By Distribution Channel, 2021 - 2033, (USD Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Million)

6. Global Glycosylated Peptide Market, By Region, 2021 - 2033, (USD Million)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, By Region, 2022 - 2033
- Regional Trends
North America
- Market Size and Forecast, By Product, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
  - U.S.
  - Canada
Europe
- Market Size and Forecast, By Product, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, By Product, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
  - China
  - Japan
  - India
  - ASEAN
  - Australia
  - South Korea
  - Rest of APAC
Latin America
- Market Size and Forecast, By Product, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Market Size and Forecast, By Product, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Size and Forecast, By Product, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Million)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Company Profiles
- Pfizer Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Bachem Holding AG
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- GlyTech, Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Sussex Research Laboratories Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Samsung Bioepis
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Celltrion Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies